ABSTRAK
INTRODUCTION
Dengue fever (DF) and dengue hemorrhagic fever (DHF) are infectious diseases caused by dengue virus with clinical manifestations of fever, muscle and joint pain that is accompanied with leukopenia, rash, lymphadenopathy, thrombocytopenia and hemorrhagic diathesis. Plasma leakage in DHF is characterized by hemoconcentration (increased hematocrit) or accumulation of fluid in the body cavity. Dengue shock syndrome is dengue hemorrhagic fever which characterized by shock (Suhendro, Nainggolan, Chen 2006) . Dengue hemorrhagic fever was first identified in 1950s in Thailand and Philippines. In Southeast Asia, DHF becomes major cause of hospitalization and death in children. Approximately 1.8 billion (over 70%) population of the world are at risk of suffering from dengue fever, especially in the Southeast Asia and the Western Pacific region (WHO 2009 ).
In Indonesia, 150,000 cases were reported in 2007 (highest record in Indonesia) with the highest cases occurred in Jakarta and West Java, with fatality rate reaches 1% (WHO 2009 ). According to the Health Department, from January until March 5, 2004, the total dengue cases in all provinces in Indonesia has reached 26 015, with as many as 389 deaths (CFR = 1.53%). The highest case was reported in DKI Jakarta (11.534 people) while the CFR was highest in NTT Province (3.96%) (MOH 2004) . In the period 2001 to 2007, there were a total of 4,332,731 cases of dengue in over 30 countries in Americas. The number of dengue cases in the same period was 106 037, with the death toll reached 1,299 people, while the rate case fatality rate reached 1.2% (PAHO 2008) .
IgM antibodies first appeared in immunoglobulin isotope. These antibodies were detected in 50% of patients within 3-5 days when disease symptoms begin to appear, and then increased up to 80% on day 5 and 99% on day 10. Serum anti-dengue IgG is generally detected at low titers at the end of the first week of disease, then increased slowly, and serum IgG was detected after a few months, even forever. During secondary infection, where the infection has been previously infected with dengue virus or dengue virus non-vaccine , IgG antibodies were detected at a high level. The early stages of healing IgM levels were lower in the secondary infection significantly rather than primary infection. To distinguish primary and secondary infection, IgM and IgG results are now used more frequently than the haemagglutination-inhibition (HI) test (WHO 2009) . By using the WHO standards, IgM and IgG profiles were studied to identify prevalence of patients with primary and secondary infection of dengue fever in the Department of Internal Medicine, Dr. Soetomo Hospital, Surabaya.
MATERIALS AND METHODS
This was a descriptive observational study aimed to reveal serum IgM and IgG profiles in patients with dengue fever by using secondary data. Data were obtained from Medical Health Document of the patients in the form of name, gender, date of hospitalization, physical examination data, laboratory examination data, including the results of serum IgM and IgG antibodies at the Department of Internal Medicine, Dr. Sutomo Hospital, Surabaya, from January 1, 2010 to December 31, 2010.
Samples were taken by simple random sampling from the population that fulfilled the inclusion criteria, ie patients who have been treated for at least 5 days after the symptoms of dengue fever, patient who has performed serological antibody anti-dengue IgM and IgG, patients had complete DMK (Medical Documents health). Then the data was collected and categorized based on the results of serum IgM and IgG antibodies. (Vaughn 1997) . In this study, patients with secondary infections had more severe clinical presentation. This was indicated by the results of a positive manifestation of bleeding and lower platelet examination. Thus, the results of this study was consistent with the literatures (Vaughn 1997) .
RESULTS
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CONCLUSION
Examination of serum IgM and IgG revealed that most (70%) of the patients had secondary infections and 30% had primary infection. It is due to the presence of dengue virus serotype diversity as well as the shift of the dominant serotype of dengue virus in Surabaya. Clinical features in patients with secondary infections tend to be more severe than that in patients with primary infection. This is indicated by the symptoms of more bleeding and lower platelet count.
